Janssen Sciences Ireland Uc

Janssen Sciences Ireland Unlimited Company

Katholieke Universiteit Leuven

Janssen Pharmaceuticals, Inc.

Janssen R&d Ireland

Medivir Ab

Janssen Products, LP

Tibotec Pharmaceuticals Ltd.

Janssen Pharmaceutica Nv

Tim Hugo Maria Jonckers

Pierre Jean-Marie Bernard Raboisson

Scott D Kuduk

Abdellah Tahri

David Craig McGowan

Stefaan Julien Last

Lili Hu

Ludwig Paul Cooymans

Sandrine Marie Helene Vendeville

Werner Embrechts

Serge Maria Aloysius Pieters

Samuël Dominique Demin

Bart Rudolf Romanie Kesteleyn

Jean-François Bonfanti

Dorothée Alice Marie-Eve Bardiot

Arnaud Didier M Marchand

Koen Vandyck

Jérôme Émile Georges Guillemont

Werner Constant Johan Embrechts

Ioannis Nicolaos Houpis

Jaromir Vlach

Steven Maurice Paula Van Hoof

Herman Augustinus De Kock

David Craig Mc Gowan

Judith Baumeister

Wendy Mia Albert Balemans

Christophe Francis Robert Nestor Buyck

Geerwin Yvonne Paul Haché

Gerben Albert Van 't Klooster

Paul Jozef Gabriel Maria Boonants

Dominique Louis Nestor Ghislain Surleraux

Piet Tom Bert Paul Wigerinck

Wim Gaston Verschueren

Jerôme Emile Georges Guillemont

Edgar Jacoby

Guillaume Jean Maurice Mercey

Jan Martin Berke

Pierre Jean-Marie Raboisson

Samuel Dominique Demin

Wim Bert Griet Schepens

Karl Magnus Nilsson

Erwin Coesemans

Zhanling Cheng

Horst Wahling

Antoine Benjamin Michaut

Yannick Debing

Inge Dierynck

Sandrine Céline Grosse

Werner Constant J Embrechts

Abdellah Tahari

Beate Sabine Hallenberger

David Mc Gowan

Florence Marie Herschke

Gang Deng

Mourad Daoubi Khamlichi

Jennifer Chiyomi Sasaki

Anna Winqvist

Carolina Martinez Lamenca

Bengt Christian Sund

Bart Henri Theresia Stoops

Pedro Manuel Passos Pinho

Leen Anna Maria Vandekerckhove

Steven Maurice Van Hoof

Jacques Armand Henri Bollekens

Laurent Calmus

Laurent Jacques Emile Calmus

Michel Obringer

Christelle Catherine Cecile Doebelin

Jérôme Émile Georges Guilllemont

Pierre Jean-Marie-Bernard Raboisson

Morgan Charles R Lecomte

Serge Marie Aloysius Pieters

Sarah Sauviller

Karen Maria Vergauwen

Michael Pelcman

Frederik Pauwels

Yanping Xu

Yimin Jiang

Lindsey Graham Deratt

Jérôme ÉMile Georges Guillemont

Gerben Albert Eleutherius Van 'T Klooster

Horst Jürgen WÄHLING

Judith Eva Baumeister

Geerwin Yvonne Paul HachÉ

The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), Ris a Calkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, Calkyl, or Calkoxy, the carbon of Rbonded to the amine in the 4-position of the quinazoline is in (R)-configuration, Ris hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, Ris hydrogen or deuterium, Ris hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, Cheterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, Cheterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, Ris hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R, R, Rand Ris not hydrogen. 

2,4-diaminoquinazoline derivatives and medical uses thereof

This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.

Pyrimidine derivatives for the treatment of viral infections

The application relates to amide derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection: 

Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases

The present invention relates to 2'-spirothietane nucleosides, and the phosphates and the prodrugs thereof, and the pharmaceutically acceptable salts and solvates thereof, and the use of such compounds as a medicament, in particular in the prevention and/or treatment of viral infections caused by viruses belonging to the Flaviviridae family and/or to the alphavirus genus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, and to the compositions or preparations for use as a medicament, more preferably for the prevention or treatment of viral infections caused by viruses belonging to the Flaviviridae family and/or to the alphavirus genus. The invention also relates to processes for the preparation of the compounds. 

Spirothietane nucleosides

This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.

Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

Aryl substituted pyrimidines for use in influenza virus infection

The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.

This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Dihydropyranopyrimidines for the treatment of viral infections

This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.

Pyrimidine prodrugs for the treatment of viral infections and further diseases

The present invention concerns mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases

Growing community of inventors

Heist-op-den-Berg, Belgium

Tim Hugo Maria Jonckers